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ABSTRACT 
Objective: To determine simultaneously the content of crystallinity of Abacavir sulphate (ABC), Lamivudine (LMD) and Zidovudine (ZVD) using X-
ray Powder Diffraction (XRPD) technique and to validate the developed analytical methods and to statistically perform correlations by ANOVA 
technique.  
Methods: Characteristic non-interfering peaks of ABC, LMD and ZVD were identified by using X-Ray Powder Diffraction method for assessment of 
the content of crystallinity.  
Results: A working range 70 % to 130 % was taken for the establishment of linearity of the ABC, LMD and ZVD in the formulation and the 
coefficient of regression of ABC was 0.999, LMD was 0.998 and ZVD was 0.998. The F value by ANOVA was found to be within limits and satisfactory.  
Conclusion: The developed method was adapted to the samples exposed to 40 °C/75 % RH, accelerated stability conditions and hence proved that 
it can be used for monitoring real-time samples. 
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INTRODUCTION 
Solid state studies of active pharmaceutical ingredients are vital 
during the research and development of a suitable large scale 
preparative technique and dosage form or a drug since 
polymorphism impacts three key areas during drug development 
and dosage form selection. These three areas include (1) the 
stability of the drug (both the physical and the chemical stability of 
the drug) in the dosage form, (2) the solubility of the drug (which 
includes the bioavailability of the drug from the site of absorption), 
and (3) the application and selection of a specific manufacturing 
process for a drug and its corresponding dosage form. 
Polymorphs are chemically identical, but have different crystal 
lattice energies, melting points, intrinsic solubility, the rate of 
dissolution, densities, mechanical properties, physicochemical 
stability, hygroscopicity and different crystal habits. Solid drug 
forms have implications not only on biopharmaceutical performance 
and on the method of manufacture but also on intellectual property. 
There are several practical examples in the pharmaceutical industry, 
where unwanted polymorphic changes caused bio-availability 
differences or intellectual litigations.  
A three-drug combination of Abacavir sulphate, Lamivudine and 
Zidovudine includes two nucleoside reverse transcriptase inhibitor 
and one non-nucleoside reverse transcriptase inhibitor as a fixed 
dosage form used in the effective management of Human 
Immunodeficiency Virus (HIV) infection in adults [1]. Abacavir 
sulphate, chemically known as [(1R)-4-[2-amino-6-(cyclopropyl amino)-
9H-purin-9-yl)-2- cyclopenetene]-1-methanol, is a carbocyclic synthetic 
analogue [2]. The active triphosphate metabolites of Abacavir sulphate, 
namely Lamivudine (4-amino-1-((2R, 5S-2-hydroxymethyl)-1,3-
oxathiolan-5-yl)pyrimidin-2-(1H)-one) [3] and Zidovudine (3-azido-
3-deoxythymidine) [4] and acts against HIV by inhibiting the reverse 
transcriptase. LMD reported existing in three crystalline forms [5-8] 
namely from I, II and III, where Form I is obtained from Form II by 
dissolving in hot water. Synthetic process yield form II. Form III 
obtained by controlled cooling of form I in a hot saturated solution 
of water. 
Only one simultaneous RP-HPLC method [9] for combined dosage 
forms of ABC, LMD and ZVD in tablet dosage forms was reported in 
the literature.  
No detailed solid state characterization of ABC, LMD and ZVD by X-
Ray diffraction was reported in the literature and hence it was 
thought worthwhile to perform the physical characterization of ABC, 
LMD and ZVD and its tablet formulation to ascertain the most stable 
form of API during pre-formulation and in tablet formulation. 
MATERIALS AND METHODS 
The three drugs ABC, LMD and ZVD were confirmed using X-Ray 
Powder Diffraction (XRPD). The working ranges 70 %-130 % were 
prepared accurately using Sensitive high Microbalance (Mettler 
Toledo XP2U, Max 2.1g-Min-1 mg). 
XRPD analysis 
Diffraction patterns were collected using Bruker D8 advance X-ray 
diffractometer with Cu anode and Lynx eye detector. ABC, LMD and 
ZVD were scanned from 3 ° 2θ to 45 ° 2θ, with step size 0.01 2θ and 
time per step of 1.4 sec for the identification purpose. After selecting 
the non-interfering peak, the patterns of spiked standards were 
collected from 3 ° 2θ to 25 ° 2θ, with step size 0.01 2θ and time per 
step of 1.4 sec. The instrument was operated at 40 kV generator 
voltages and 40 mA generator current. Variable divergent slit and 
Anti-scattering slit were used of V20 mm, Nickel filter was used in the 
secondary beam path. Eva (version 10.0 revision I) which is part of the 
Diffrac software package was used for data processing and evaluation. 
The chemical structures of ABC, LMD and ZVD are represented in fig. 
1. Spiked standard working range concentrations 70 % to 130 % 
were prepared by geometrical mixing of ABC, LMD, ZVD and 
placebo.  
Validation 
Validation Studies were done with 70 %, 95 %, 105 % and 130 % 
concentrations of ABC, LMD and ZVD in formulation and linearity, 
specificity, recovery and precision were established. 
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Statistical calculation 
The validation results were used to calculate the Regression 
Analysis and ANOVA values by using Microsoft Excel Analysis data 




Fig. 1: Chemical structure of ABC, LMD and ZVD 
 
RESULTS AND DISCUSSION 
Knowledge of the solid state is of great importance in the 
development of a new active pharmaceutical ingredient since the 
solid form often dictates the properties and performance of the drug. 
Pharmaceutical substances are known to exist in different solid-
state forms, and there are many analytical techniques available to 
characterize the solid-state pharmaceuticals and their solid-state 
transformations. Solid-state characterization technique is used to 
detect and quantitate physical forms of drugs as such and in solid 
dosage forms.  
In the present study, we described, X-Ray Powder Diffraction 
(XRPD) technique to identify physical forms of ABC, LMD and ZVD 
and to detect the physical forms within the formulations, 
development of methods for physical quantification forms of drugs 
within formulations. Development of a method to detect and 
quantitate the undesired form, Form-I in Form-II of LMD in API, 
development of a method to estimate the content of crystallinity of 
the three API’s in the formulation was also described in the study. 
The developed methods were validated to determine the statistical 
reliabilities of them. 
The appearance of sharp peaks in XRPD for the three drugs ABD, 
LMD and ZVD confirmed their crystallinity, and they were identified 
and characterized with XRPD and overlayed with a formulation to 
identify characteristic non-interfering peaks (fig. 2). 
 
 
Fig. 2: Overlay diffractogram patterns of ABC, LMD, ZVD, 
placebo and formulation 
 
The calibration curves (fig. 3, 4 and 5) were drawn by plotting 
working range standard preparations against net area (counts per 
seconds (Cps) x 2θ °). Diffractogram overlay of 70 % to 130 % 
working range standard preparations is represented in fig. 6. The 
standard calibration curve for ABC, LMD and ZVD was found to be 
linear over a working range of concentrations 70 %-130 %. The 
correlation coefficient (R2) was 0.999 for ABC, 0.998 for LMD and 
0.998 for ZVD which are well within the acceptable limit.  
Four standard preparations at 70 %, 95 %, 105 % and 130 % 
concentrations, Prep 1, Prep 8, Prep 9 and Prep 7 respectively were 
prepared and measurements are recorded for three replicates and 
corresponding peaks of ABC, LMD and ZVD were integrated for the 
evaluation of precision, recovery, accuracy and reproducibility 
(table 1). The mean recovery values of 96.5 % for ABC, 100.3 % for 
LMD and 101.97 % for ZVD were obtained. The average recovery for 
each drug was above 99 %.  
 
 
Fig. 3: Calibration plot of ABC 
 
 
Fig. 4: Calibration plot of LMD 
 
 
Fig. 5: Calibration plot of ZVD 
 
Regression statistics were evaluated for working range 
concentrations prepared for validation versus Net area of each peak 
obtained. Regression parameters Multiple R, R2, Adjusted R2 and 
Standard error, were calculated. The correlation coefficient R 
(Multiple R), R2 and Adjusted R2 values for ABC, LMD and ZVD were 
given in table 2. Analysis of variance (ANOVA) table for the 
regression is constructed and is represented in table 2. 
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Fig. 6: Overlay diffractogram pattern of preparations, working range 70 % to 130 % for assessing the crystallinity in tablet formulation 
 
Table 1: Precision, accuracy and reproducibility data of ABC, LMD and ZVD 
Drug  Preparations Concentration Average Average  % RSD 
Area Recovery 
Abacavir sulphate  Prep-1 130.38 5.363 97.1148 0.5698 
Prep-8 105.14 4.425 99.5350 0.3883 
Prep-9 95.04 3.378 93.5821 0.2007 
Prep-7 70.02 2.574 97.5606 0.5186 
Lamivudine Prep-1 70.21 0.2813 100.47 0.2762 
Prep-8 95.17 0.6547 97.8961 0.3274 
Prep-9 105.04 0.8873 102.1218 0.5688 
Prep-7 129.69 1.2783 100.9836 0.8662 
Zidovudine Prep-1 69.5 1.2160 109.5 1.4 
Prep-8 94.9 1.5107 100.4 0.6 
Prep-9 104.77 1.6490 99.5 0.8 
Prep-7 129.99 2.0147 98.5 1.2 
The low %RSD value obtained by the three measurements of each of the concentration of ABC, LMD and ZVD indicates that the method is precise 
and reproducible. 
 
Table 2: Regression statistics ABC, LMD and ZVD 
Parameters ABC LMD ZVD 
Multiple R 0.999 0.999 0.999 
R Square 0.999 0.998 0.998 
Adjusted R Square 0.999 0.997 0.998 
Standard Error 0.026 0.016 0.013 
Observations 7 7 7 
 
Table 3: XRPD Crystallinity study content instability batches of ABC, LMD and ZVD 
 Abacavir sulphate  Lamivudine Zidovudine 
 Net area  % recovery  % RSD Net Area  % recovery  % RSD Net area  % recovery  % RSD 
Initial 4.199  0.36 0.744  0.80 1.573  0.15 
15 D 4.175 99.42 0.74 99.46 1.571 99.87 
30 D 4.17 99.30 0.733 98.52 1.569 99.74 
45 D 4.166 99.26 0.73 98.11 1.566 99.55 
60 D 4.159 99.22 0.726 97.58 1.566 99.55 
 
In order to assess the real-time application of the developed XRPD 
method it has been adopted in the determination of the crystalline 
content of drug formulation of unknown compositions initially and 
kept at 40 °C, 75 % RH stability conditions. The results are evaluated 
from their respective calibration models. The results obtained are 
tabulated in table 3. From the results obtained we conclude that the 
proposed method can be applied easily to analyze a large number of 
samples to determine crystallinity content of drug product. 
CONCLUSION 
X-ray powder diffraction technique is a very promising technique to 
identify, characterize and assess percentage crystallinity of the 
active pharmaceutical ingredient in tablet formulations. The 
developed XRPD method was able to measure the crystallinity 
content accurately. Regression statistics and ANOVA calculations 
proved the statistical reliability of the method. 
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